Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 9/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 4/20 | 0.45 |
| ▸ | RARB | P10826 | 4/20 | 0.45 |
| ▸ | RARG | P13631 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411672 | 0.92 | HPGD (0.50) | CYP26A1CYP26B1HPGDRECQLRARA | |
| SCHEMBL13411673 | 0.89 | CYP26A1 (0.45) | CYP26A1CYP26B1HPGDRECQLRARA | |
| SCHEMBL13411674 | 0.89 | CYP26A1 (0.45) | CYP26A1CYP26B1RARARARBRARG | |
| SCHEMBL13411648 | 0.86 | CYP26A1 (0.55) | CYP26A1CYP26B1HPGDRECQLRARA | |
| SCHEMBL13411688 | 0.85 | CYP26A1 (0.54) | CYP26A1CYP26B1RARARARBRARG | |
| SCHEMBL13411654 | 0.84 | CYP26A1 (0.53) | CYP26A1CYP26B1HPGDRECQLRARA | |
| SCHEMBL13411655 | 0.83 | CYP26A1 (0.52) | CYP26A1CYP26B1RARARARBRARG | |
| SCHEMBL13411657 | 0.83 | CYP26A1 (0.52) | CYP26A1CYP26B1RARARARBRARG | |
| SCHEMBL2790410 | 0.83 | NPC1 (0.58) | CYP26A1CYP26B1RARARARBRARG | |
| SCHEMBL13411666 | 0.82 | RAB9A (0.52) | CYP26A1CYP26B1RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | claimed |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2102162-A1 | PHENYLIC DERIVATIVES AND USE THEREOF AS DRUGS | IPSEN PHARMA S.A.S. (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008059128-A1 | PHENYLIC DERIVATIVES AND USE THEREOF AS DRUGS | IPSEN PHARMA S.A.S. (FR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059128-A1 | PHENYLIC DERIVATIVES AND USE THEREOF AS DRUGS | IPSEN PHARMA S.A.S. (FR) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | CNR2, CNR1, TRPV1 | CYP26A1 451/4885CYP26B1 368/4885HPGD 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.